• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology

    8/7/25 9:25:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care
    Get the next $MMSI alert in real time by email

    SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology.

    The Prelude Wave is the latest innovation in Merit's comprehensive Access portfolio, which includes a wide range of dilators, micro-access systems, sheath introducers, and guide sheaths. A low-profile, hydrophilic sheath with best-in-class insertion and sheath retention, the Prelude Wave with SnapFix technology is designed with features which may aid in the reduction of arterial spasm and occlusion as physicians perform radial access procedures.

    Radial access offers many well-documented benefits compared to the femoral approach,1 but there remain opportunities to improve patient outcomes, as radial artery spasm (narrowing) and occlusion (blockage) can still occur.

    Radial artery spasm is reported in up to 20% of patients,2 and approximately 4.6% will have a radial artery occlusion,3 both of which can lead to patient discomfort and other complications.4,5 Sheath features, such as a hydrophilic coating, a low profile, and tapered transitions have been shown to help reduce the risks of radial artery spasm and occlusion as well as improve patient comfort.1,6

    In addition, securement devices utilized to stabilize hydrophilic sheaths during procedures have been linked to reported issues in 30% of cases, leading to procedural inefficiency.7 A securement device specifically developed for sheaths may help alleviate the challenges physicians face.

    To meet these clinical needs, Merit innovated the Prelude Wave, a next-generation sheath with a unique securement feature. Compared to the leading competitor, the Prelude Wave offers twice the lubricity, twice the resistance to buckling and kinking, and requires 40% less insertion force.8 A first of its kind, SnapFix technology provides twice the adhesive strength, with physicians rating its performance and ease of use superior to the leading competitor.8

    Learn more about the Prelude Wave with SnapFix Technology.

    "Prelude Wave addresses challenges interventionalists see when performing radial procedures," said Morton Kern, MD, MSCAI, FACC, FAHA, Interventional Cardiologist at Veterans Administration Long Beach Health Care System in Long Beach, CA, and a consultant of Merit. "A sheath and securement solution that may help minimize these risks, while also offering strong radial access performance, provides physicians with a meaningful product option that creates a better treatment experience for patients."

    To further support a radial-first approach, Merit has tailored its portfolio with solutions that complement existing products, designed to address physicians' toughest clinical challenges. A recent example of this was Merit's acquisition of StatSeal®, a patented hemostatic sealant used to protect access sites, as seen in radial procedures.

    "Whether by design or acquisition, we always strive to advance innovation in our Access portfolio, providing our healthcare partners with solutions that support data-driven approaches to treatment," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "The Prelude Wave with SnapFix Technology is a superior product built to champion radial procedures, manufactured with features designed to aid in minimizing common vascular access challenges. We're proud to continue offering radial technology advancements for physicians and their patients."

    ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.

    TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

    Any forward-looking statements set forth in this release are subject to risks and uncertainties such as those described in Merit's filings with the U. S. Securities and Exchange Commission ("SEC"). For a further discussion of the risks and uncertainties which may affect Merit's business, operations and financial condition, see Part I, Item 1A, "Risk Factors" in Merit's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, Part II, Item 1A, "Risk Factors" in Merit's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC and Merit's other filings with the SEC. Actual results will likely differ, and may differ materially, from anticipated results.

    CONTACTS

    PR/Media Inquiries

    Sarah Comstock

    Merit Medical

    +1-801-432-2864 | [email protected] 

    INVESTOR INQUIRIES

    Mike Piccinino, CFA, IRC

    Westwicke - ICR

    +1-443-213-0509 | [email protected]

    References

    1. Rathore et al. 2010. "Impact of Length and Hydrophilic Coating of the Introducer Sheath on Radial Artery Spasm during Transradial Coronary Intervention." JACC Cardiovasc Interv 3, no. 5 (May): 475 ̶ 83. doi: 10.1016/j.jcin.2010.03.009.
    2. Randall and Boudoulas. "Reducing Radial Spasm." Society for Cardiovascular Angiography & Interventions (2024 Sep 19).
    3. Pitta, Sharma, and Boudoulas. "Newer Emerging Strategies to Reduce Radial Artery Occlusion: Post-Transradial Catheterization." Society for Cardiovascular Angiography & Interventions (2025 Jun 19).
    4. Zus et al. 2024. "Radial Artery Spasm—A Review on Incidence, Prevention and Treatment." Diagnostics (Basal) 14, no 17 (Aug 29): 1897. doi: 10.3390/diagnostics14171897.
    5. Tsigkas et al. 2023. "Preventing and Managing Radial Artery Occlusion Following Transradial Procedures: Strategies and Considerations." J Cardiovasc. Dev Dis. 10, no. 7 (Jun 30): 283. doi: 10.3390/jcdd10070283.
    6. Mason et al. 2018. "An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement from the American Heart Association." Cir Cardiovasc Interv 11, no. 9 (Sept): e000035. doi: 10.1161/HCV.0000000000000035.
    7. Kern et al. 2020. "Securing the Radial Sheath: An Update on a Pesky but Persistent Little Problem." Cath Lab Digest (Nov).
    8. Data on File.


    Primary Logo

    Get the next $MMSI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MMSI

    DatePrice TargetRatingAnalyst
    3/28/2025$120.00Overweight
    Analyst
    12/11/2024$103.00 → $120.00Equal Weight → Overweight
    Wells Fargo
    6/28/2024$96.00Outperform
    Robert W. Baird
    4/11/2024$88.00Buy
    CL King
    2/7/2024$87.00Neutral
    BofA Securities
    12/21/2023$100.00Hold → Buy
    Canaccord Genuity
    12/20/2022$73.00 → $72.00Buy → Hold
    Canaccord Genuity
    2/25/2022$73.00 → $72.00Outperform
    Raymond James
    More analyst ratings

    $MMSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Merit Medical with a new price target

    Analyst initiated coverage of Merit Medical with a rating of Overweight and set a new price target of $120.00

    3/28/25 8:20:21 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously

    12/11/24 7:56:29 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Robert W. Baird initiated coverage on Merit Medical with a new price target

    Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00

    6/28/24 8:04:44 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ward Lynne N. exercised 2,433 shares at a strike of $34.46 and sold $206,536 worth of shares (2,433 units at $84.89) (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    8/12/25 12:12:22 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    CFO AND TREASURER Parra Raul Jr. exercised 15,181 shares at a strike of $59.43 and sold $1,423,219 worth of shares (15,181 units at $93.75) (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    6/17/25 5:57:11 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    President and CEO Lampropoulos Fred P. sold $38,244 worth of shares (400 units at $95.61), decreasing direct ownership by 0.04% to 1,045,628 units (SEC Form 4)

    4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)

    6/12/25 6:11:05 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    SEC Filings

    View All

    $MMSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $MMSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SEC Form 10-Q filed by Merit Medical Systems Inc.

    10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    7/30/25 4:19:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    7/30/25 4:15:49 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)

    7/11/25 4:07:25 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    First Patient Enrolled in Merit Medical's WRAPSODY (WRAP) North America Registry

    The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE).The first WRAP North America patient was enrolled at Bluff City Vascular, an interventional nephrology and vascular access center in Memphis, TN. SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today the successful enrollment of the first patient in the WRAP North America registry. The WRAP North America registry is designed to enroll up to 250 US and Canadian patients on hemodialysis who experie

    8/18/25 9:25:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology

    SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology. The Prelude Wave is the latest innovation in Merit's comprehensive Access portfolio, which includes a wide range of dilators, micro-access systems, sheath introducers, and guide sheaths. A low-profile, hydrophilic sheath with best-in-class insertion and sheath retention, the Prelude Wave with SnapFix technology is designed with features which may aid in the reduction of arterial spasm and occlusion as physicians perform radi

    8/7/25 9:25:00 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance

    Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. ("Biolife"), a manufacturer of hemostatic devices branded as StatSeal® and WoundSeal®Martha Aronson named as new President and Chief Executive Officer, effective October 3, 2025 † Comparisons above are calculate

    7/30/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Financials

    Live finance-specific insights

    View All

    Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance

    Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. ("Biolife"), a manufacturer of hemostatic devices branded as StatSeal® and WoundSeal®Martha Aronson named as new President and Chief Executive Officer, effective October 3, 2025 † Comparisons above are calculate

    7/30/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Names Martha Aronson as New President and Chief Executive Officer

    Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit's new President and Chief Executive Officer, effective October 3, 2025. Fred P. Lampropoulos will remain as Chairman of the Board, President and CEO of Merit through October 3, 2025. Upon Ms. Aronson's appointment, Mr. Lampropoulos will continue to serve as Chairman of the Board. "I am pleased to welcome Martha to Merit," said Mr.

    7/7/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025

    SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using th

    7/3/25 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Leadership Updates

    Live Leadership Updates

    View All

    Merit Medical Announces Resignation of President, Joseph Wright

    SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI

    12/16/24 4:00:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Shareholders Elect Silvia M. Perez as New Director

    SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven

    5/16/24 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    Merit Medical Executive Leadership Team Update

    Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit

    5/15/24 4:05:00 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    $MMSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merit Medical Systems Inc.

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    11/14/24 11:05:03 AM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    2/13/24 5:09:38 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Merit Medical Systems Inc. (Amendment)

    SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)

    2/12/24 5:32:43 PM ET
    $MMSI
    Medical/Dental Instruments
    Health Care